Nivolumab: A Review in Advanced Nonsquamous Non-Small Cell Lung Cancer.

Abstract

The programmed death (PD)-1 immune checkpoint inhibitor nivolumab (Opdivo(®)) is approved in the USA for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) who have progression on or after platinum-based chemotherapy and in the EU for the treatment of adults with locally advanced or metastatic NSCLC after prior chemotherapy. In previously-treated patients with advanced nonsquamous NSCLC, overall survival was significantly prolonged and the overall response rate was significantly higher in patients who received intravenous nivolumab 3 mg/kg every 2 weeks versus intravenous docetaxel in the pivotal CheckMate 057 trial. Progression-free survival did not significantly differ between patients receiving nivolumab and those receiving docetaxel. Intravenous nivolumab had a manageable adverse event profile (including immune-mediated adverse events) and was better tolerated than docetaxel in the CheckMate 057 trial. Thus, nivolumab is an important new option for use in previously-treated patients with advanced nonsquamous NSCLC.

• Authors: Gillian M Keating
• Journal: Drugs (Drugs) Vol. 76 Issue 9 Pg. 969-78 (Jun 2016) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 27189706 (Publication Type: Journal Article, Review)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents
• Nivolumab

Topics

• Antibodies, Monoclonal (administration & dosage, pharmacology)
• Antineoplastic Agents (therapeutic use)
• Carcinoma, Non-Small-Cell Lung (drug therapy)
• Clinical Trials, Phase II as Topic
• Clinical Trials, Phase III as Topic
• Disease Progression
• Humans
• Nivolumab